FINANCIAL OVERVIEW FIRST QUARTER 2026* • Revenue amounted to SEK 17.3 m (93.2). • Other operating income was SEK 1.7 m (8.8). • EBITDA amounted to SEK -7.8 m (32.6). • R&D costs amounted to SEK −9.9 m (−22.8), corresponding to 52 percent (67) of total operating costs. • The loss for the period was SEK 13.1 m (+8.2). • Earnings per share was SEK 0.01 (0.1). • Cash and cash equivalents at the end of the period amounted to SEK 66.7 m (24.7).
*Figures in parentheses refer to the corresponding period of the previous year.
SIGNIFICANT EVENTS DURING
THE FIRST QUARTER 2026
• On March 31, Xbrane released a revised timeline for resubmission of the BLA application for its ranibizumab biosimilar to the U.S. Food and Drug Administration (FDA). It is estimated that the ap plication can be resubmitted in April–May 2026, when the contract manufacturer is expected to have completed all outstanding tasks associated with a previous Complete Response Letter (CRL). The processing time at the agency is then esti mated to be six months.
SIGNIFICANT EVENTS
AFTER THE END OF THE QUARTER
• In April, the company announced that it had resubmitted its Biologics License Application (BLA) to the U.S. Food and Drug Administra tion for its biosimilar candidate to Lucentis® (ranibizumab).
• In May, the Company announced that it had revised the agreement with its collaboration partner Intas, whereby Intas will assume f inancing of certain CMC-related develop ment activities. The agreement entails that all costs financed by Intas, including an accumulated markup of 18% per annum, will be deducted from future profit-sharing payments. Intas is also granted the option, instead of profit sharing, to elect a lump-sum payment equivalent to 40 months of forecast profit sharing. Otherwise, Xbrane’s and Intas’s respective commitments remain unchanged in accordance with the original license agreement.
Web cast
If you wish to participate via audiocast please use the link below. Via the audiocast you are able to ask written questions.
Q1 Report 2026